Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Immunogenicity and anti-drug antibodies in peptides

Name: Immunogenicity and anti-drug antibodies in peptides
Published: 2026-10-27

Why impurities and aggregates can make the immune system react to a peptide

Evidence verdict: Mechanism and risk-assessment methods are established in regulatory science; clinical rates for unapproved products are unknown.

Last reviewed: Oct 27, 2026

In 30 seconds

Even approved peptide drugs can trigger anti-drug antibodies; labels report measured rates. [Regulatory]
Synthesis impurities (insertions, deletions, side-chain changes) can create new T-cell epitopes. FDA asks generic makers to assess them. [Regulatory, Lab]
FDA cites immunogenicity as a reason BPC-157, thymosin alpha-1 and ipamorelin are on its compounding safety-risk list. [Regulatory]
Unapproved products have no impurity profile, no immunogenicity testing and no antibody monitoring. Their risk is unknown (UNVERIFIED).

How it happens

Synthetic peptides can carry product-related impurities with amino acid insertions, deletions and side-chain modifications that may alter immunogenicity (PMID 39185315). [Lab] Reviews describe how such impurities can add T-cell epitopes and set out a framework for assessing risk (PMID 37467878). [Review] Trace innate-immune-modulating impurities can activate immune cells (PMID 40398094). [Lab]

What regulators require

FDA guidance on ANDAs for highly purified synthetic peptides referencing rDNA-origin drugs lets generic makers address immunogenicity by characterizing impurity differences with in silico and in vitro tools; teriparatide and salmon calcitonin are worked examples (PMIDs 41445733, 39185315). [Regulatory, Lab]

Why it matters clinically

Anti-drug antibodies can neutralize a drug, change its clearance, or rarely cross-react with a natural hormone. Consequences are drug-specific and are reported in each approved label (UNVERIFIED for unapproved products).

FDA compounding concerns

FDA's safety-risk page cites immunogenicity for BPC-157 and thymosin alpha-1 for certain routes, and aggregation-driven immunogenicity for ipamorelin acetate (FDA safety-risk page). [Regulatory]

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document. [Controlled study] randomized trial or systematic review of trials. [Observational] market surveillance, pharmacovigilance or cohort data. [Lab] cell, analytical or animal work. [Case] single case report.

Endotoxins and TFA salts, Peptide degradation, storage and cold chain

References

Roberts et al. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods. Front Pharmacol. 2024. PMID 39185315.
De Groot AS, et al. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discov Today. 2023. PMID 37467878.
Tang et al. Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide). Biochem Biophys Res Commun. 2025. PMID 40398094.
Mattei et al. Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. Front Immunol. 2025. PMID 41445733.
US FDA guidance. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin (docket FDA-2017-D-5767), as described in PMIDs 41445733 and 39185315.
US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.